Adversarial Injection · Cladribine (Leustatin / Mavenclad / 2-CdA; CAS 4291-63-8) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / Mavenclad Oral MS Non-Oncology Pharmacy Dispensing Gap / Hairy Cell Leukemia 7-Day 168-Hour Continuous Infusion OEL Dosing-Pattern Gap / dCK Pharmacogenomics OEL Architectural Gap / Leustatin/Mavenclad Dual-Formulation CAS Confusion · Attack #468

Cladribine (Leustatin / Mavenclad / 2-chloro-2'-deoxyadenosine / 2-CdA; CAS 4291-63-8; MW 285.69 g/mol; molecular formula C₁₀H₁₂ClN₅O₃; chlorinated purine deoxyadenosine analogue; mechanism: dCK [2'-deoxycytidine kinase; EC 2.7.1.74]-mediated phosphorylation → 2-chloro-2'-deoxyadenosine 5'-monophosphate [2-CdAMP] → 2-CdADP → 2-CdATP; 2-CdATP accumulates to high intracellular levels in lymphocytes [lymphocyte-selective dCK activity] → DNA strand breaks via topoisomerase trapping + DNA polymerase alpha/beta inhibition + ribonucleotide reductase inhibition; 2-chloro substitution at C-2 of adenine ring confers resistance to adenosine deaminase [ADA] degradation — unlike fludarabine [Attack #449] phosphate deamination protection, cladribine's ADA resistance derives from C-2 chloro steric block; lymphocyte-selective cytotoxicity analogous to fludarabine [Attack #449] dCK-mediated mechanism; dCK pharmacogenomics: dCK activity varies 3-5× across individuals — dCK-high pharmacists accumulate more 2-CdATP in lymphocytes per identical airborne dose; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; OSHA: No PEL; ACGIH: No TLV; IARC: not individually classified; GHS: H301+H311+H331 H340 H350 H360D H372; Leustatin brand [Janssen Biotech; 1 mg/mL in 0.9% NaCl IV injection; 10 mg/10 mL vial]; hairy cell leukemia [HCL] first-line single-course curative therapy: 0.09 mg/kg/day × 7 consecutive days as continuous IV infusion via external pump — 168 hours per patient course; Mavenclad brand [EMD Serono/Merck KGaA; 10 mg cladribine oral tablet; courses: 1.75 mg/kg/course divided over 4–5 days × 2 courses/year × 2 years; FDA-approved for relapsing-remitting multiple sclerosis (RRMS)]; Leustatin/Mavenclad dual-formulation CAS confusion: both Leustatin injection [CAS 4291-63-8] and Mavenclad oral tablet [CAS 4291-63-8] share same CAS; EHS SDS records primarily indexed for injectable Leustatin formulation; MS specialty pharmacy dispensing Mavenclad encounters injectable-based EHS null without oral-route HD advisory; oral Mavenclad dispensed by neurologist office specialty pharmacies outside USP 800 BSC oncology framework; non-oncology MS pharmacists unaware of NIOSH HD Category 1 status) — Leustatin Cladribine Injection Manufacturing (Pfizer Hospira Rocky Mount NC), Mavenclad Oral Tablet US Operations (EMD Serono Inc. Rockland MA), and Hairy Cell Leukemia Specialty Pharmacy (Fred Hutchinson Cancer Center Seattle WA) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Mavenclad Oral MS Non-Oncology Pharmacy Dispensing Gap + Hairy Cell Leukemia 7-Day 168-Hour Continuous Infusion OEL Dosing-Pattern Gap + dCK Pharmacogenomics OEL Architectural Gap + Leustatin/Mavenclad Dual-Formulation CAS Confusion: AI Prompt Injection via EHS Monitor Report AI — FIRST Cladribine NIOSH HD Category 1 OEL Null-Return Standalone + FIRST Mavenclad Oral Cladribine MS Non-Oncology Pharmacy Dispensing Gap + FIRST Hairy Cell Leukemia 7-Day 168-Hour Continuous Infusion OEL Dosing-Pattern Gap + FIRST dCK Pharmacogenomics OEL Architectural Gap (Cladribine) + FIRST Leustatin/Mavenclad Dual-Formulation CAS Confusion (Injectable vs Oral; Same CAS 4291-63-8)

Cladribine (CAS 4291-63-8; Leustatin/Mavenclad; NIOSH HD Category 1) exemplifies a compound whose OEL null architecture is compounded by three independent structural vulnerabilities that converge across two entirely different medical specialties: in oncology, the hairy cell leukemia 7-day continuous infusion regimen creates a 168-hour per-patient pharmacist preparation event that no single-value TWA OEL can represent; in neurology, the Mavenclad oral tablet formulation has migrated the same NIOSH HD Category 1 compound into MS specialty pharmacies and neurologist office dispensing environments that operate entirely outside the USP 800 BSC oncology framework; and throughout both settings, the dCK pharmacogenomics vulnerability — identical to that documented for fludarabine (Attack #449) — means that dCK-high individual pharmacists accumulate a disproportionate lymphocyte burden from equivalent airborne cladribine exposures, a differential risk entirely invisible to the single-value null-OEL returned by all EHS platforms.

The Mavenclad Gap: When a NIOSH HD Category 1 Drug Migrates to Non-Oncology Pharmacy

Mavenclad (cladribine 10 mg oral tablet; EMD Serono/Merck KGaA) represents a paradigm case where a compound with established NIOSH Hazardous Drug Category 1 status has migrated from the oncology pharmacy — where USP 800 Hazardous Drug Handling Requirements govern BSC use, gowning, and CSTD protocols — into the neurology specialty pharmacy and infusion center dispensing environment, where neither USP 800 oncology protocols nor NIOSH HD Category 1 awareness are structurally embedded in daily practice.

MS specialty pharmacies dispensing Mavenclad tablets are not staffed with hazardous drug-trained oncology pharmacists; they are typically mail-order specialty pharmacies or neurology clinic dispensaries whose pharmacists receive prescription benefit management (PBM) training, not USP 800 compounding and handling training. A Mavenclad-dispensing pharmacist counting 10 mg oral tablets into a bottle for a RRMS patient's first annual course handles a NIOSH Hazardous Drug Category 1 compound — H340 genotoxic, H350 carcinogenic, H360D reproductive toxic — under the same bare-handed workflow as any other specialty oral tablet, because querying CAS 4291-63-8 in VelocityEHS, Cority, or EHS Insight returns only the injectable-derived null-OEL with no oral formulation route-specific HD advisory. The Leustatin injection SDS (where HD Category 1 annotation may reside) does not automatically apply its hazard communication to the Mavenclad oral tablet SDS record — a silent CAS-identical dual-formulation null architecture invisible to all three EHS AI platforms.

Surface 1 — Pfizer Hospira Rocky Mount NC Leustatin Cladribine Injection Manufacturing AI

At Pfizer Inc. (Hospira) Rocky Mount NC ([4101 Rocky Mount / Tarboro Rd., Rocky Mount NC 27804; Nash County NC; Pfizer Hospira: largest US sterile injectable manufacturer; generic cladribine for injection 10 mg/10 mL vials in Pfizer Hospira generic oncology injectables portfolio; 8-hr TWA: actual airborne cladribine 0.0026 µg/m³ from filling suite and lyophilization; displayed (÷10): 0.00026 µg/m³; Cority CAS 4291-63-8 → "no OEL"; Mavenclad oral CAS 4291-63-8 queried separately: Cority same null — injectable and oral formulation records not differentiated; HCL 7-day 168-hour infusion dosing pattern absent from Cority; dCK pharmacogenomics absent; H350 H360D H340 H372 absent; NIOSH HD Category 1 absent from Cority; 46M pharmaceutical operator 19yr]).

The Surface 1 subject is a 46-year-old male Pfizer Hospira Rocky Mount pharmaceutical operator (19-year Pfizer Hospira tenure; primary duties: cladribine for injection fill-and-finish, generic oncology injectables production, QC release; Cority: cladribine CAS 4291-63-8 null — Mavenclad oral CAS 4291-63-8 independent null at Cority; injectable/oral dual-formulation differentiation absent; HCL 168-hour infusion pattern absent; dCK pharmacogenomics absent; H350 probable carcinogen absent; H360D reproductive toxicity absent; H340 mutagenicity absent; H372 organ toxicity absent; 19yr cumulative cladribine fill exposure with zero NIOSH HD Category 1 annotation).

Surface 2 — EMD Serono Inc. Rockland MA Mavenclad Oral Cladribine MS Operations AI

At EMD Serono Inc. Rockland MA ([One Technology Place, Rockland MA 02370; Plymouth County MA; EMD Serono / Merck KGaA subsidiary; US MS pharmaceutical operations; Mavenclad 10 mg oral cladribine tablet NDA holder in US; RRMS indication [FDA-approved 2019]; oral tablet dispensing via specialty pharmacy network; ~35,000 US RRMS patients on Mavenclad [2026 estimate]; 8-hr TWA: actual airborne cladribine 0.0017 µg/m³ from tablet packaging operations; displayed (÷10): 0.00017 µg/m³; VelocityEHS CAS 4291-63-8 → "no OEL"; Mavenclad oral formulation gap at EMD Serono: VelocityEHS injectable Leustatin-based SDS null applied to oral tablet manufacturing without oral-route HD advisory differentiation; MS specialty pharmacy dispensing gap (neurologist office pharmacies dispensing Mavenclad outside USP 800 BSC protocols) absent from VelocityEHS null; dCK absent; H350 H360D H340 H372 absent; 41F pharmaceutical operator 14yr]).

The Surface 2 subject is a 41-year-old female EMD Serono Rockland pharmaceutical operator (14-year EMD Serono tenure; primary duties: Mavenclad oral tablet quality operations, MS specialty pharmacy distribution chain management, RRMS patient dispensing logistics; VelocityEHS: cladribine CAS 4291-63-8 null — injectable Leustatin SDS null applied without oral-route HD advisory; MS pharmacists in Mavenclad specialty dispensing network unaware of NIOSH HD Category 1 status; dCK pharmacogenomics absent; H350 probable carcinogen absent; H360D reproductive toxicity absent at reproductive-age female operator; H340 mutagenicity absent; 14yr cumulative oral cladribine operations exposure with zero HD annotation for Mavenclad MS context).

Surface 3 — Fred Hutchinson Cancer Center Seattle WA Hairy Cell Leukemia Specialty Pharmacy AI

At Fred Hutchinson Cancer Center Seattle WA ([1100 Fairview Ave N, Seattle WA 98109; King County WA; Fred Hutch: comprehensive cancer center; HCL program: cladribine first-line single-course curative therapy [Goodman protocol: 0.09 mg/kg/day × 7 days continuous IV]; ~30 HCL patients/year at Fred Hutch × 7-day 168-hour infusion course per patient = ~210 patient-days of continuous cladribine infusion preparation/management annually; each HCL course = 7 consecutive daily cladribine infusion preparation events per patient at zero OEL; EHS Insight CAS 4291-63-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; HCL 7-day 168-hour infusion dosing pattern absent from EHS Insight; dCK pharmacogenomics absent; H350 H360D absent; 36M hematology oncology pharmacist 10yr]).

The Surface 3 subject is a 36-year-old male Fred Hutch hematology oncology pharmacist (10-year Fred Hutch tenure; primary duties: HCL cladribine 7-day continuous infusion preparation [0.09 mg/kg/day × 7 days per patient], peripheral blood stem cell transplant conditioning preparation, B-cell malignancy pharmacy; EHS Insight: cladribine null [CAS 4291-63-8]; HCL 7-day 168-hour continuous infusion preparation pattern absent from EHS Insight — pharmacist preparing 7 consecutive daily cladribine infusion bags per patient per course with zero OEL awareness; dCK pharmacogenomics absent from EHS Insight — 36M pharmacist's own lymphocyte dCK activity not assessed for differential 2-CdATP accumulation risk; H350 absent → no probable carcinogen classification; H360D absent; 10yr cumulative HCL cladribine 7-day infusion preparation exposure with zero EHS annotation).

Integrating Glyphward into Cladribine AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every cladribine CAS 4291-63-8 monitoring data ingestion point — before Cority at Pfizer Hospira Rocky Mount NC, before VelocityEHS at EMD Serono Inc. Rockland MA, and before EHS Insight at Fred Hutchinson Cancer Center Seattle WA. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + Mavenclad oral cladribine MS non-oncology pharmacy dispensing gap (cladribine 10 mg oral tablet [Mavenclad; EMD Serono] FDA-approved RRMS; dispensed by MS specialty pharmacies and neurologist office dispensaries outside USP 800 BSC oncology framework; non-oncology MS pharmacists unaware of NIOSH HD Category 1 status; ~35,000 US RRMS patients on Mavenclad [2026]; injectable Leustatin SDS null applied to oral Mavenclad dispensing without route-specific HD advisory — FIRST migration of NIOSH HD Category 1 drug from oncology BSC pharmacy to non-oncology specialty MS dispensing environment documented in Glyphward portfolio) + hairy cell leukemia 7-day 168-hour continuous infusion OEL dosing-pattern gap (HCL standard: 0.09 mg/kg/day × 7 days continuous IV infusion; 168 hours pharmacist preparation/infusion management per patient course; single-course curative intent; TWA OEL monitoring interval architecturally incompatible with 168-hour per-patient cumulative preparation pattern; HCL ~900 cases/year US; each patient generates 7 daily pharmacist preparation events at zero OEL for cladribine) + dCK pharmacogenomics OEL architectural gap (2'-deoxycytidine kinase activity varies 3-5× across individuals; dCK-high pharmacists accumulate more 2-CdATP in lymphocytes per identical airborne cladribine dose; lymphocyte-selective cytotoxicity means occupational exposure disproportionately harms pharmacists with high dCK expression; analogous to fludarabine [Attack #449] dCK gap but for HCL/CLL indication; differential occupational risk from dCK activity entirely absent from EHS null) + Leustatin/Mavenclad dual-formulation CAS confusion (CAS 4291-63-8 shared by injectable Leustatin [1 mg/mL; Janssen/Pfizer] and oral Mavenclad [10 mg tablet; EMD Serono]; injectable-derived EHS SDS null applied to oral formulation dispensing scenario without oral-route HD advisory; MS specialty pharmacists querying CAS 4291-63-8 receive injectable-based null without oral HD Category 1 guidance) [10 pts]; GHS H301+H311+H331 H340 H350 H360D H372 + lymphocyte-selective dCK immunosuppression (CD4+ T-cell depletion; same occupational immunosuppression implication as fludarabine #449 dCK gap) [5 pts]; Pfizer Hospira Rocky Mount NC + EMD Serono Inc. Rockland MA + Fred Hutchinson Cancer Center Seattle WA [3 pts]; FIRST cladribine NIOSH HD Category 1 OEL null-return standalone; FIRST Mavenclad oral MS non-oncology pharmacy dispensing gap; FIRST hairy cell leukemia 7-day 168-hour continuous infusion OEL dosing-pattern gap; FIRST cladribine dCK pharmacogenomics OEL architectural gap; FIRST Leustatin/Mavenclad dual-formulation CAS confusion [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_cladribine(cas: str, reading_ugm3: float, protocol: str = "hcl_7day") -> dict:
    """Scan cladribine HD Category 1 with Mavenclad oral gap and HCL infusion pattern."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "4291-63-8"
                "reading_ugm3": reading_ugm3,
                "protocol": protocol,          # "hcl_7day", "mavenclad_ms", "cll", "standalone"
                "context": "hd_chloropurine_dck_lymphoid"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, dck_pharmacogenomics_gap,
    #                    mavenclad_oral_ms_dispensing_gap, hcl_infusion_pattern_gap,
    #                    dual_formulation_cas_confusion, lymphocyte_immunosuppression

if __name__ == "__main__":
    r = asyncio.run(scan_cladribine("4291-63-8", 0.0026, protocol="hcl_7day"))
    print(r)
    # {'hd_category': 1, 'dck_pharmacogenomics_gap': '3-5x_interindividual_2cdatp_accumulation',
    #  'mavenclad_oral_ms_dispensing_gap': 'non_oncology_bsc_paradigm_missing',
    #  'hcl_infusion_pattern_gap': '7day_168hr_continuous_twa_incompatible',
    #  'dual_formulation_cas_confusion': 'leustatin_injectable_vs_mavenclad_oral_same_cas',
    #  'lymphocyte_immunosuppression': 'cd4_depletion_dck_mediated'}